within Pharmacolibrary.Drugs.ATC.J;

model J01CA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.13,
    adminDuration  = 600,
    adminMass      = 2.0,
    adminCount     = 1,
    Vd             = 0.0184,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Mezlocillin is a broad-spectrum, semisynthetic penicillin antibiotic used primarily for the treatment of serious infections caused by susceptible Gram-negative and Gram-positive organisms, including Pseudomonas aeruginosa. It was previously widely used in hospitalized patients, particularly for intra-abdominal, urinary tract, and lower respiratory tract infections but is now largely withdrawn from the market and not approved in most countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li>Yue-E Wu, Wei Zhao,'Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants'-authors' response.,The Journal of antimicrobial chemotherapy,2022<a href='https://pubmed.ncbi.nlm.nih.gov/36205004/'>https://pubmed.ncbi.nlm.nih.gov/36205004/</a></li><li>Jing Zhou, Li Jiang, Zhi Ling Zhang, Zhao Rui Wang, Yan Xiu Zhang, Xu Lin, Bo Hao Tang, Bu Fan Yao, Zi Xuan Guo, Jing Jing Yang, John Van Den Anker, Yue E Wu, Wei Zhao,Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants.,The Journal of antimicrobial chemotherapy,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35662337/'>https://pubmed.ncbi.nlm.nih.gov/35662337/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01CA10;
